市場調查報告書
商品編碼
1373362
血栓切除設備市場 - 按產品類型、按應用、最終用途 - 全球預測,2023-2032 年Thrombectomy Devices Market - By Product Type, By Application, By End-use - Global Forecast, 2023-2032 |
在持續的技術進步以及微創和高效設備不斷發展的推動下,血栓切除設備市場規模從 2023 年到 2032 年將以 7.3% 的年複合成長率成長。
全球醫療保健支出不斷成長,加上先進醫療技術的日益採用,正在促進醫療機構對最新、最有效的治療方案的投資不斷增加。此外,由於高度重視改善患者護理和治療結果,醫療機構正在分配大量資源來採購最新的血栓切除設備,進一步促進市場擴張。
血栓切除設備產業分為產品類型、應用、最終用途和地區。
根據產品類型,預計2023 年至2032 年間,凝塊抽取導管細分市場的市場規模將獲得顯著成長。這一成長可歸因於凝塊抽取導管提供有效、微創凝塊清除解決方案的強大能力,以促進精確的凝塊清除解決方案。以及在各種心血管和神經血管應用中的高效血栓提取。
此外,用於增強導航和可操作性的不斷進步的技術進步將有助於該細分市場的成長。例如,2023 年 6 月,Penumbra 獲得 FDA 批准推出其 Lightning Bolt 7 動脈血栓切除系統,該系統採用調節抽吸功能,透過壓力感測器去除血栓。
預計在 2023 年至 2032 年間,血栓切除設備市場將見證神經血管血栓切除術應用領域的牽引。這是由於缺血性中風和動脈瘤等神經血管疾病的盛行率不斷上升。隨著人們越來越關注提高神經血管治療的療效和降低相關風險,對用於複雜的神經血管手術的先進血栓切除設備的需求激增。這可能會推動該細分市場的成長。
從地區來看,在醫療保健支出增加和心血管疾病發病率上升的推動下,歐洲血栓切除設備產業將在 2032 年實現強勁成長。根據世界衛生組織報告,歐盟每年發現超過600萬例CVD病例,超過170萬人死於循環系統疾病,約佔總死亡人數的37%。對技術進步和創新醫療設備的採用的高度重視正在促進血栓切除術在臨床環境中的廣泛整合。此外,支持性的監管架構和有利的報銷政策也鼓勵歐洲國家採用血栓切除設備。
.3.2.2.1。嚴格規定
.3.2.2.2。產品成本高
Thrombectomy Devices Market size is poised to expand at 7.3% CAGR from 2023 to 2032, driven by the ongoing technological advancements along with the rising development of minimally invasive and efficient devices.
The growing healthcare expenditure worldwide coupled with the increasing adoption of advanced medical technologies is facilitating the rising investments in latest and most effective treatment options by healthcare facilities. Additionally, with the strong focus on enhancing patient care and outcomes, healthcare institutions are allocating significant resources to procure the latest thrombectomy devices, further fostering the market expansion.
The thrombectomy devices industry is segmented into product type, application, end-use, and region.
Based on product type, the market size from the clot extraction catheter segment is projected to gain significant traction between 2023 and 2032. The growth can be attributed to the strong ability of clot extraction catheters to provide effective and minimally invasive clot removal solutions for facilitating precise and efficient thrombus extraction in various cardiovascular and neurovascular applications.
Additionally, the rising technological advancements for enabling enhanced navigation and maneuverability will contribute to the segment growth. For instance, in June 2023, Penumbra received FDA approval for the launch of its Lightning Bolt 7 arterial thrombectomy system deployed with regulated aspiration to remove blood clots with pressure sensors.
Thrombectomy devices market is anticipated to witness traction from the neurovascular thrombectomy application segment between 2023 and 2032. This is attributed to the rising prevalence of neurovascular conditions, such as ischemic strokes and aneurysms. With the increasing focus on improving the efficacy of neurovascular treatments and reducing associated risks, there is surging demand for advanced thrombectomy devices for adoption in intricate neurovascular procedures. This is likely to propel the segment growth.
Regionally, Europe thrombectomy devices industry will record robust growth through 2032 driven by the increasing healthcare expenditure and the rising incidence of cardiovascular diseases. According to the WHO report, every year across the EU, more than 6 million cases of CVD are identified, and over 1.7 million people die from circulatory system disorders, accounting for around 37% of all fatalities. The strong emphasis on technological advancements and the adoption of innovative medical devices are facilitating the widespread integration of thrombectomy procedures in clinical settings. Moreover, supportive regulatory frameworks and favorable reimbursement policies are also encouraging the adoption of thrombectomy devices across European countries.